Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 226

1.

Uncontrolled hypertension among patients managed in primary healthcare facilities in Kinshasa, Democratic Republic of the Congo.

Kika TM, Lepira FB, Kayembe PK, Makulo JR, Sumaili EK, Kintoki EV, M'Buyamba-Kabangu JR.

Cardiovasc J Afr. 2016 Nov/Dec;27(6):361-366. doi: 10.5830/CVJA-2016-036.

2.

Diet Soda Consumption and Risk of Incident End Stage Renal Disease.

Rebholz CM, Grams ME, Steffen LM, Crews DC, Anderson CA, Bazzano LA, Coresh J, Appel LJ.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):79-86. doi: 10.2215/CJN.03390316. Epub 2016 Oct 26.

PMID:
27797893
3.

Facing the Metabolic Syndrome Epidemic in Living Kidney Donor Programs.

Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM, Alberú J, Morales-Buenrostro LE.

Ann Transplant. 2016 Jul 22;21:456-62.

4.

[Physical exercise in diabetic nephropathy].

Suzuki S.

Nihon Rinsho. 2016 Apr;74 Suppl 2:197-201. Japanese. No abstract available.

PMID:
27266087
5.

Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community.

Nayor M, Wang N, Larson MG, Vasan RS, Levy D, Ho JE.

J Am Heart Assoc. 2015 Dec 31;5(1). pii: e002347. doi: 10.1161/JAHA.115.002347.

6.

Glucometabolic disease in the kidney transplant patient.

Sadhu AR, Steenkamp D, McDonnell ME.

Front Biosci (Schol Ed). 2016 Jan 1;8:67-78. Review.

PMID:
26709897
7.

Prevalence and determinants of the metabolic syndrome among subjects with advanced nondiabetes-related chronic kidney disease in Gran Canaria, Spain.

Boronat M, Bosch E, Lorenzo D, Quevedo V, López-Ríos L, Riaño M, García-Delgado Y, García-Cantón C.

Ren Fail. 2016;38(2):198-203. doi: 10.3109/0886022X.2015.1117904. Epub 2015 Dec 1.

PMID:
26627145
8.

Metabolic Syndrome-Associated Risk Factors and High-Sensitivity C-Reactive Protein Independently Predict Arterial stiffness in 9903 Subjects With and Without Chronic Kidney Disease.

Tsai SS, Lin YS, Lin CP, Hwang JS, Wu LS, Chu PH.

Medicine (Baltimore). 2015 Sep;94(36):e1419. doi: 10.1097/MD.0000000000001419.

9.

Metabolic syndrome and chronic kidney disease.

Belarbia A, Nouira S, Sahtout W, Guedri Y, Achour A.

Saudi J Kidney Dis Transpl. 2015 Sep;26(5):931-40. doi: 10.4103/1319-2442.164573.

10.

Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.

Mohamed R, Jayakumar C, Chen F, Fulton D, Stepp D, Gansevoort RT, Ramesh G.

J Am Soc Nephrol. 2016 Mar;27(3):745-65. doi: 10.1681/ASN.2014111136. Epub 2015 Sep 2.

11.

PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Nasrallah R, Hassouneh R, Hébert RL.

J Am Soc Nephrol. 2016 Mar;27(3):666-76. doi: 10.1681/ASN.2015050528. Epub 2015 Aug 28. Review.

12.

Evaluating central blood pressure in dialysis patients.

Jimi K, Tomiyama H, Miyaoka Y, Watanabe K, Kotobuki T, Kanno Y.

Kidney Int. 2015 Jul;88(1):193. doi: 10.1038/ki.2015.90. No abstract available.

PMID:
26126091
13.

Association of low vitamin D levels with metabolic syndrome in hemodialysis patients.

Ahmadi F, Damghani S, Lessan-Pezeshki M, Razeghi E, Maziar S, Mahdavi-Mazdeh M.

Hemodial Int. 2016 Apr;20(2):261-9. doi: 10.1111/hdi.12316. Epub 2015 May 20.

PMID:
25991066
14.

Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration in elderly subjects with metabolic syndrome.

Kocełak P, Olszanecka-Glinianowicz M, Owczarek AJ, Krupa W, Obirek P, Bożentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Skalska A, Więcek A, Chudek J.

Pol Arch Med Wewn. 2015;125(6):402-13. Epub 2015 Apr 29.

15.

[Association between obesity and chronic renal disease].

Navarro G, Ardiles L.

Rev Med Chil. 2015 Jan;143(1):77-84. doi: 10.4067/S0034-98872015000100010. Review. Spanish.

17.

Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases.

Berezin A, Zulli A, Kerrigan S, Petrovic D, Kruzliak P.

Clin Biochem. 2015 Jun;48(9):562-8. doi: 10.1016/j.clinbiochem.2015.02.003. Epub 2015 Feb 16. Review.

PMID:
25697107
18.

Acetaminophen attenuates glomerulosclerosis in obese Zucker rats via reactive oxygen species/p38MAPK signaling pathways.

Wang C, Blough E, Arvapalli R, Dai X, Triest WE, Leidy JW, Masannat Y, Wu M.

Free Radic Biol Med. 2015 Apr;81:47-57. doi: 10.1016/j.freeradbiomed.2015.01.008. Epub 2015 Jan 19.

PMID:
25614458
19.

[Study of the metabolic syndrome and obesity in hemodialysis patients].

Quero Alfonso AI, Fernández Gallegos R, Fernández Castillo R, Gomez Jimenez FJ, García Rios Mdel C, García García I.

Nutr Hosp. 2014 Oct 23;31(1):286-91. doi: 10.3305/nh.2015.31.1.8207. Spanish.

20.

Obesity, metabolic health, and the risk of end-stage renal disease.

Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, Warnock DG, Judd SE, Gutiérrez OM.

Kidney Int. 2015 Jun;87(6):1216-22. doi: 10.1038/ki.2014.384. Epub 2014 Dec 17.

Supplemental Content

Loading ...
Support Center